State Street
IMVT icon

State Street’s Immunovant IMVT Stock Holding History

State Street’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$178M Buy
4,617,005
+79,076
+2% +$2.41M 0.01% 1120
2026
Q1 		$113M Buy
4,537,929
+751,003
+20% +$19.4M ﹤0.01% 1312
2025
Q4 		$96.3M Buy
3,786,926
+894,308
+31% +$19.9M ﹤0.01% 1383
2025
Q3 		$46.6M Buy
2,892,618
+62,544
+2% +$1.01M ﹤0.01% 1755
2025
Q2 		$45.3M Sell
2,830,074
-257,021
-8% -$3.89M ﹤0.01% 1728
2025
Q1 		$52.8M Buy
3,087,095
+389,573
+14% +$8.15M ﹤0.01% 1597
2024
Q4 		$66.8M Sell
2,697,522
-324,820
-11% -$9.21M ﹤0.01% 1573
2024
Q3 		$86.2M Buy
3,022,342
+303,386
+11% +$8.95M ﹤0.01% 1410
2024
Q2 		$71.8M Sell
2,718,956
-922,951
-25% -$26.3M ﹤0.01% 1461
2024
Q1 		$118M Buy
3,641,907
+425,531
+13% +$15.5M 0.01% 1205
2023
Q4 		$136M Sell
3,216,376
-252,241
-7% -$9.28M 0.01% 1094
2023
Q3 		$133M Buy
3,468,617
+234,448
+7% +$5.3M 0.01% 995
2023
Q2 		$61.4M Sell
3,234,169
-733,436
-18% -$13.7M ﹤0.01% 1534
2023
Q1 		$61.5M Buy
3,967,605
+854,662
+27% +$14.8M ﹤0.01% 1506
2022
Q4 		$55.3M Buy
3,112,943
+2,234,342
+254% +$28.1M ﹤0.01% 1558
2022
Q3 		$4.9M Sell
878,601
-14,079
-2% -$68.8K ﹤0.01% 3071
2022
Q2 		$3.48M Buy
892,680
+56,938
+7% +$246K ﹤0.01% 3272
2022
Q1 		$4.61M Sell
835,742
-1,947,052
-70% -$12.1M ﹤0.01% 3222
2021
Q4 		$23.7M Sell
2,782,794
-1,329,000
-32% -$11M ﹤0.01% 2347
2021
Q3 		$35.7M Sell
4,111,794
-278,843
-6% -$2.52M ﹤0.01% 2045
2021
Q2 		$46.4M Buy
4,390,637
+774,877
+21% +$10.8M ﹤0.01% 1901
2021
Q1 		$58M Buy
3,615,760
+1,746,740
+93% +$46.1M ﹤0.01% 1631
2020
Q4 		$86.3M Buy
1,869,020
+717,555
+62% +$33.2M 0.01% 1259
2020
Q3 		$40.5M Buy
1,151,465
+819,890
+247% +$24.7M ﹤0.01% 1606
2020
Q2 		$8.07M Buy
+331,575
New +$7.11M ﹤0.01% 2537

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

State Street's IMVT Position: Q2 2026 in Review

State Street increased its Immunovant (IMVT) stake by 1.7% in Q2 2026, buying an estimated $2.41M and bringing the position to 4,617,005 shares worth $178M. The position accounts for 0.01% of the portfolio, ranked #1120.

State Street first reported a position in IMVT in Q2 2020 and has held it in 25 quarters since. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • State Street held 4,617,005 shares of Immunovant worth $178M as of Q2 2026.
  • State Street bought 79,076 Immunovant shares in Q2 2026, an estimated $2.41M.
  • Immunovant made up 0.01% of State Street's portfolio in Q2 2026, its #1120 holding.
  • State Street first reported a position in Immunovant in Q2 2020 and has held it in 25 quarters since.
  • 226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.